文献速递临床试验与 GCP流行病学与生物统计

3期交叉试验在ClinicalTrials.gov的注册与报告特征分析

Registration of phase 3 crossover trials on ClinicalTrials.gov.
PubMed 文献 · Trials · 2020-07-06

该研究检索ClinicalTrials.gov截至2019年8月6日注册的3期随机交叉试验,纳入124项并提供结果与发表链接。分析显示三分之二为AB|BA设计,78%提供足够受试者流程信息,85%主要结局和80%不良事件按干预报告。结论强调注册与报告需考虑配对设计特征,并为良好报告指南提供依据。

要点

  • 3期交叉试验注册与报告应体现配对设计特征。
  • 多数试验为AB|BA简单交叉设计,需明确受试者流程。
  • 主要结局与不良事件宜按干预分别报告。

核心结论

  • 随机交叉试验的注册和报告必须考虑设计的配对性质。
  • 观察结果和建议为交叉试验良好报告实践指南的制定提供了依据。

研究设计与样本

  • 检索ClinicalTrials.gov截至2019年8月6日注册的3期随机交叉试验,要求提供结果、注册至少一个主要结局并包含至少一篇结果发表链接。
  • 两名评价员独立评估资格并提取信息至系统评价数据存储库中的电子表格。
  • 共分析124项交叉试验。

主要发现

  • 三分之二试验为简单的AB|BA序贯设计。
  • 78%(97/124)的试验提供了足够信息以理解整个试验的受试者流程。
  • 基线特征最常以所有受试者作为单一组报告(52%,65/124)。
  • 主要结局最常按干预报告(85%,105/124)。
  • 不良事件最常按干预报告(80%,99/124)。

临床怎么用

  • 注册和报告交叉试验时应明确描述配对设计及受试者流程。
  • 主要结局和不良事件建议按干预分别报告以体现配对特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a randomized crossover trial, each participant is randomized to a sequence of treatments and treatment effect is estimated based on within-individual difference because each participant serves as his/her own control. This feature makes the design and reporting of randomized crossover trials different from that of parallel trials. Our objective was to characterize phase 3 crossover trials with results reported on ClinicalTrials.gov and identify issues and best practices for reporting. METHODS: We searched ClinicalTrials.gov for phase 3 randomized crossover trials that provided results, registered at least one primary outcome, and included at least one link to a results publication in the record by August 6, 2019. Two reviewers independently assessed the eligibility and extracted information from each record into an electronic form developed and maintained in the Systematic Review Data Repository. RESULTS: Of the 124 crossover trials analyzed, two thirds were a simple "Intervention A then B" or "Intervention B then A" (AB|BA) design. Most trials (78%, 97/124) provided enough information to understand the participant flow throughout the trial. Baseline characteristics were most often reported for all participants as a single group (52%, 65/124). Primary outcomes and adverse events were most commonly reported "per intervention" (85%, 105/124, and 80%, 99/124, respectively). CONCLUSIONS: The registration and reporting of randomized crossover trials must account for the paired nature of the design. Our observations and recommendations informed the development of guidelines for good reporting practices in the registration and reporting of randomized crossover trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zeng L, Qureshi R, Viswanathan S, et al. Registration of phase 3 crossover trials on ClinicalTrials.gov. Trials. 2020. PMID: 32631413. doi:10.1186/s13063-020-04545-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。